Articles From: October Average Transaction Price Reaches Highest Mark of 2014 to Ocwen Launches REALPortal(R) Platform


Cars.com reports SUV and truck sales propel new-car market to YTD highs CHICAGO , Nov.
Sign-up for October Average Transaction Price Reaches Highest Mark of 2014 investment picks
2014/11/12
NEW YORK , Nov.
Sign-up for October Sees Further Consolidation in Commodity Markets investment picks
By Tess Stynes American Airlines Group Inc. and Southwest Airlines Co.
Sign-up for October traffic edges up at American, Southwest investment picks
Ocular Therapeutix (Nasdaq: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will provide an overview of the Company at the 21st Annual BioCentury Conference during a live presentation at 3:30pm ET on September 26, 2014.
Sign-up for Ocular Therapeutix to Present at the 21st Annual NewsMakers in the Biotech Industry Investment Conference on Friday, September 26 investment picks
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced top line results for a Phase 2 clinical trial evaluating Sustained Release Dexamethasone (OTX-DP) for treatment of allergic conjunctivitis.
Sign-up for Ocular Therapeutix™ Announces Top-Line Results from Phase 2 Sustained Release Dexamethasone Trial for Allergic Conjunctivitis investment picks
Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced today completion of enrollment for its two Phase 3 clinical trials evaluating Sustained Release Dexamethasone (OTX-DP) for treatment of ocular inflammation and pain following cataract surgery.
Sign-up for Ocular Therapeutix™ Completes Enrollment in Phase 3 Sustained Release Dexamethasone Trials for Post-Operative Inflammation and Pain investment picks
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced today enrollment of the first patients in a Phase 2b clinical trial evaluating Sustained Release Travoprost (OTX-TP) for the reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension.
Sign-up for Ocular Therapeutix™ Enrolls First Patients in Phase 2b Clinical Trial for Sustained Release Travoprost for the Treatment of Glaucoma and Ocular Hypertension investment picks
Ocular Therapeutix (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the third quarter ended September 30, 2014, and provided an update on current business developments.
Sign-up for Ocular Therapeutix™ Reports Third Quarter 2014 Financial Results investment picks
Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will present at the Ophthalmology Innovation Summit (OIS) at AAO on October 16 th , 2014 at 11:35 AM.
Sign-up for Ocular Therapeutix™ to Attend American Academy of Ophthalmology Annual Meeting in Chicago, Illinois investment picks
Ocular Therapeutix (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will be presenting at two upcoming investor conferences: About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology.
Sign-up for Ocular Therapeutix™ to Participate in Two Investor Conferences in November 2014 investment picks
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer 25th Annual Healthcare Conference on Thursday, December 11, 2014 at 3:20 p.m. Eastern Time at the Crowne Plaza Hotel in New York City.
Sign-up for Ocular Therapeutix™ to Present at Oppenheimer 25th Annual Healthcare Conference investment picks
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter 2014 financial results on Wednesday, November 12, 2014 at 7:00 a.m. Eastern Time.
Sign-up for Ocular Therapeutix™ to Report Third Quarter 2014 Financial Results and Provide Business Updates on Wednesday, November 12, 2014 investment picks
New GramaDerm™ Solution and Hydrogel to be introduced at Medica Trade Fair on November 12-15 in Dusseldorf, Germany Oculus now offering four clinically proven dermatology products with acne spray, acne gel, scar management and atopic dermatitis to European dermatologists ROERMOND, Netherlands and PETALUMA, Calif., Nov.
Sign-up for Oculus Innovative Sciences Commercializes Microcyn(R)-Based Solution and Hydrogel for Treatment of Mild-to-Moderate Acne in Europe investment picks
• New Pediacyn™ Hydrogel to be Introduced at Medica Education Conference on November 12-15 in Dusseldorf, Germany ROERMOND, Netherlands and PETALUMA, Calif., Oct.
Sign-up for Oculus Innovative Sciences Receives European CE Mark for New Microcyn(R)-Based Atopic Dermatitis Hydrogel investment picks
New Epicyn™ Hydrogel to be Introduced at Medica Trade Fair on November 12-15 in Dusseldorf, Germany ROERMOND, Netherlands and PETALUMA, Calif., Nov.
Sign-up for Oculus Innovative Sciences Receives European CE Mark for New Microcyn(R)-Based Scar Management Hydrogel investment picks
Total revenue of $3.3 million for the second quarter Net loss of $718,000, reduced from $1.4 million in same period last year Oculus owns two million shares of Ruthigen (Nasdaq:RTGN) Net worth of $13.4 million, up $11.9 million from September 30, 2013 Conference Call Begins at 4:30 p.m. (ET) Today PETALUMA, Calif., Nov.
Sign-up for Oculus Innovative Sciences Reports Financial Results for the Second Quarter of Fiscal Year 2015 investment picks
U.S. Patent for Treatment of Second- and Third-Degree Burns; U.S. and Canadian Patents for Treatment of Peritonitis; Chinese Patent for Solution Containing Hypochlorous Acid and Its Methods of Use PETALUMA, Calif., Sept.
Sign-up for Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Allowance of Four New Patents for Microcyn(R) Technology investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1150850&ProfileId=051205&sourceType=1 NEW ORLEANS, LA --
Sign-up for OCWEN 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Ocwen Financial Corp. - OCN investment picks
By James Sterngold A New York state regulator has accused the mortgage servicer Ocwen Financial Corp.
Sign-up for Ocwen backdated letters to distressed homeowners: Regulator investment picks
Ocwen Financial Corporation (NYSE:OCN) CEO Ronald Faris yesterday addressed the National Foundation for Credit Counseling (NFCC)’s 49 th Annual Leaders Conference.
Sign-up for Ocwen CEO Ronald Faris Addresses National Foundation for Credit Counseling investment picks
Completed legacy ResCap system migration Recorded $100 million charge for potential settlement with New York regulator Surpassed 500,000 loan modifications milestone ATLANTA, Oct.
Sign-up for Ocwen Financial Announces Operating Results for Third Quarter 2014 investment picks
Ocwen Financial Corporation (NYSE:OCN), the nation’s fourth largest mortgage servicer, today held the first meeting of the company’s Community Advisory Council (the “Council”) at the Capital Hilton in Washington, DC.
Sign-up for Ocwen Holds First Community Advisory Council Meeting investment picks
ATLANTA, Nov.
Sign-up for Ocwen Launches REALPortal(R) Platform investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: October Average Transaction Price Reaches Highest Mark of 2014 to Ocwen Launches REALPortal(R) Platform
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent